App-Quantinova.ai

Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN

O. Ledder - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experience

N. Plevris - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Comparative efficacy and impact on patient-reported outcomes of pharmacological therapies for moderate to severe ulcerative colitis: a systematic review and network meta-analysis

P. Paschos - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort study

S. Sebastian - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Joint Inflammatory Bowel Disease–Obstetric clinics: outcomes in 95 pregnancies at a tertiary centre over a 3-year period

T.S. Chew - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel disease

A.A. Thi - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

Tuberculin

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience

B. Feagan - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Systematic review of internet decision making resources for patients considering surgery for ulcerative colitis

D. Baker - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Does one size truly fit all? Co-prescription of allopurinol and thiopurine therapy results in variation of TGNs outside the therapeutic range in more than half of patients

E. Johnston - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Allopurinol

Sleep problems in inflammatory bowel disease; When bed becomes a battleground

A. Green - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis

S. Schreiber - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis

J. Pans - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Tasocitinib

Comparative effectiveness analysis of flares, hospitalisations, and corticosteroid use among biologic naïve patients with inflammatory bowel disease within 12 months of initiation of vedolizumab or infliximab

N. Alam - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Shifting the shunters in a paediatric inflammatory bowel disease population: thiopurine dose splitting versus allopurinol and thiopurine co-therapy

S. Chadokufa - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Allopurinol

A pilot study of the electronic patient portal “Patient Knows Best” for monitoring biologic therapy in inflammatory bowel disease

N. Kamperidis - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula

S. Sebastian - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)

C.A. Siegel - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Nutrition status in pre-surgical Crohn's disease, active Crohn's disease, Crohn's disease in remission and ulcerative colitis in remission: a cross-sectional study

A.M. Sandall - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01)

D. Wolf - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Real world use of adalimumab: effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe ulcerative colitis

G. Watts - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Adalimumab

Filters

45280 Abstracts